https://scholars.lib.ntu.edu.tw/handle/123456789/639920
標題: | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study | 作者: | Passaro, A Wang J. Wang, Y Lee, S-H Melosky, B JIN-YUAN SHIH Azuma, K Juan-Vidal, O Cobo, M Felip, E Girard, N Cortot, A B Califano, R Cappuzzo, F Owen, S Popat, S Tan, J-L Salinas, J Tomasini, P Gentzler, R D William, W N Reckamp, K L Takahashi, T Ganguly, S Kowalski, D M Bearz, A MacKean, M Barala, P Bourla, A B Girvin, A Greger, J Millington, D Withelder, M Xie, J Sun, T Shah, S Diorio, B Knoblauch, R E Bauml, J M Campelo, R G Cho, B C |
關鍵字: | EGFR-mutated; NSCLC; amivantamab; lazertinib; post-osimertinib | 公開日期: | 一月-2024 | 卷: | 35 | 期: | 1 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639920 | ISSN: | 09237534 | DOI: | 10.1016/j.annonc.2023.10.117 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。